Literature DB >> 7538216

Prostate disease: management options for the primary healthcare team. Report of a working party of the British Prostate Group.

G D Chisholm1, S J Carne, J M Fitzpatrick, N J George, J C Gingell, J W Keen, R S Kirby, D Kirk, E P O'Donoghue, W B Peeling.   

Abstract

The prostate gland has attracted a remarkable increase in interest in the past few years. The two most common diseases of this gland, benign prostatic hyperplasia and carcinoma of the prostate, have been brought into greater prominence by new diagnostic methods, public interest, and a wider choice of surgical and non-surgical treatments. Uncertainty about the significance of these changes has occurred because of the rapidity of change, the profusion of statements, opinions and promotions, and the relatively little guidance available from the profession. Ten urologists and two general practitioners have reviewed the relevant evidence about these two prostate diseases and the newer diagnostic methods; their conclusions are summarised here. Management options and guidance on clinical practice are also discussed. Because of a number of unresolved diagnostic and management issues, detailed requirements for practice guidelines have not been specified.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538216      PMCID: PMC2398180          DOI: 10.1136/pgmj.71.833.136

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  31 in total

1.  Latent carcinoma of the prostate.

Authors:  L M FRANKS
Journal:  J Pathol Bacteriol       Date:  1954-10

2.  Prostatectomy: patients' perception and long-term follow-up.

Authors:  P R Malone; A Cook; R Edmonson; M W Gill; R J Shearer
Journal:  Br J Urol       Date:  1988-03

3.  Assessment of volume measurement of the prostate using per-rectal ultrasonography.

Authors:  D R Jones; E E Roberts; G J Griffiths; M C Parkinson; K T Evans; W B Peeling
Journal:  Br J Urol       Date:  1989-11

4.  Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia.

Authors:  N P Roos; J E Wennberg; D J Malenka; E S Fisher; K McPherson; T F Andersen; M M Cohen; E Ramsey
Journal:  N Engl J Med       Date:  1989-04-27       Impact factor: 91.245

Review 5.  Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention.

Authors:  J T Isaacs
Journal:  Prostate Suppl       Date:  1990

6.  Screening for prostate cancer in 1993: is it appropriate, or not?

Authors:  G W Chodak
Journal:  Semin Urol       Date:  1993-05

7.  The natural history of untreated "prostatism".

Authors:  A J Ball; R C Feneley; P H Abrams
Journal:  Br J Urol       Date:  1981-12

8.  A population-based study of prostatectomy: outcomes associated with differing surgical approaches.

Authors:  N P Roos; E W Ramsey
Journal:  J Urol       Date:  1987-06       Impact factor: 7.450

9.  Symptom status and quality of life following prostatectomy.

Authors:  F J Fowler; J E Wennberg; R P Timothy; M J Barry; A G Mulley; D Hanley
Journal:  JAMA       Date:  1988-05-27       Impact factor: 56.272

10.  The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study.

Authors:  R J Glynn; E W Campion; G R Bouchard; J E Silbert
Journal:  Am J Epidemiol       Date:  1985-01       Impact factor: 4.897

View more
  3 in total

1.  Elevated serum prostate-specific antigen and pancreatic carcinoma.

Authors:  L R Ranganath; G A Lewis; B T Nobbs; P F Goddard; D C Rangedera
Journal:  Postgrad Med J       Date:  1996-06       Impact factor: 2.401

Review 2.  Benign prostatic hyperplasia.

Authors:  R J Simpson
Journal:  Br J Gen Pract       Date:  1997-04       Impact factor: 5.386

3.  An audit of prostate-specific antigen and clinical symptoms in general practice.

Authors:  S Ramachandran; M C Foster; D R Thomas; A K Roalfe; R A Hall
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.